Skip to navigation Skip to content

Clinical Trial: Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis


Type of MS: PPMS
Treatment mode of action: To prevent progression
Number of Subjects: 100
Medication: ocrelizumab
Location: California
Institutions: SC3 Research - Pasadena Contact Information
Roxanne Cabading, ext. 799
(626) 250 2070


F. Hoffmann-La Roche Ltd


This study will evaluate the effectiveness and safety of ocrelizumab ( Ocrevus®) compared with placebo in participants with primary progressive multiple sclerosis (PPMS), including participants later in their disease course. This study focuses on upper limit disability progression.


© 2023 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.